What Brexit Effect? UK Biotech Start-Ups Reach Record Numbers
With UK biotech venture capital investment at its highest level to date, biotech company building is showing no let up, with almost half of all UK biotech companies formed within the last three years.
You may also be interested in...
While major biotech indices went south in 2018, VC enthusiasm for biotech remained bullish. Biotech companies raised a record $22.83bn in 2018.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.